<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564941</url>
  </required_header>
  <id_info>
    <org_study_id>CICL670AHU02</org_study_id>
    <nct_id>NCT00564941</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload</brief_title>
  <official_title>Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of deferasirox in transfusion dependent
      Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This study will evaluate the safety and efficacy of deferasirox in transfusion dependent Myelodysplastic Syndrome, Beta-thalassaemia major patients with chronic iron overload</measure>
    <time_frame>monthly during the therapy and at the end of the treatment (aftr 9 months therapy)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient's compliance during the study assessed by the number of the unused tablets returned by the patient safety assessed by patient laboratory data, adverse events, serious adverse events</measure>
    <time_frame>during the treatment (9 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">309</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Beta-Thalassemia</condition>
  <arm_group>
    <arm_group_label>Deferasirox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>deferasirox</intervention_name>
    <arm_group_label>Deferasirox</arm_group_label>
    <other_name>ICL670</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  In- or outpatients with myelodysplasia / with risk of low or intermedier-1 according
             to the International Prognostic Scoring System (IPSS) confirmed by bone marrow
             evaluation within 3 month/ or beta thalassaemia major patients, who have chronic iron
             overload, as a consequence of frequent blood transfusion

          -  Serum ferritin&gt; 1800 Âµg/L

          -  Age: 18-80 years

          -  men and women

          -  Chronic iron overload caused by at least 30 units and maximum 100 units of blood of
             packed red blood cells

          -  Deferoxamin therapy is contraindicated or inadequate or unable to use in the
             recommended dose due to intolerability or other reason

          -  Eastern Cooperative Oncology Group (ECOG) performance status score between 0-2

          -  written informed consent

        Exclusion criteria:

          -  beta thalassaemia minor,

          -  haemosiderosis caused by other than chronic transfusional iron overload,

          -  patients with impaired renal function (Creatinin clearance&lt; 60 ml/ min),

          -  pregnancy,

          -  lactation,

          -  patient of childbearing potential unwilling to use contraceptive precautions

          -  known hypersensitivity to deferasirox or any ingredients,

          -  impaired hepatic function (SGOT,SGPT 5x above UNL).

          -  Patients severely ill due to underlying disease progression or other severe
             concomitant disease.

          -  Patients with poor prognosis of karyotype

          -  patients with malabsorption caused by inflammatory bowel disease, gastrectomy,
             pancreatitis or other medical condition

          -  History of nephrotic syndrome

          -  Significant proteinuria

          -  Patients with a previous history of clinically relevant ocular toxicity related to
             iron chelation

          -  Patients with positive test to HIV

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=4600</url>
    <description>Results of CICL670AHU02 from Novartis Clinical Trials website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2007</study_first_submitted>
  <study_first_submitted_qc>November 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2007</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>beta-Thalassemia</keyword>
  <keyword>Iron Overload</keyword>
  <keyword>Iron Chelating Agents</keyword>
  <keyword>deferasirox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

